Redhill Biopharma Ltd. (RDHL)
RDHL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1553846/000110465926049055/0001104659-26-049055-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RDHL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001553846 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $286K |
| Net income | -$429K |
| Operating income | -$7.9M |
| Net margin | -150.0% |
| Operating margin | -2776.9% |
| Revenue growth | -96.4% |
| Cash | $4.0M |
| Total assets | $25.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "These conditions and events indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about the Company's ability to continue as a going concern." | 20-F 2026-04-27 |
| Cash and burn | $4.0M cash; operating cash flow -$2.4M a quarter. | Report 2025-12-31 |
| Shares outstanding | 5,092,326 (2025-12-31); 1,289,983 a year earlier; 117,971 three years earlier. 3y figure adjusted for splits (1-for-25 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-08-20 | Source 2024-08-20 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-10-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-05-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 8,887,683 shares at the 2026-11-13 price; the latest SEC cover count is 5,092,326 as of 2025-12-31. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $286K | -$429K | -$9.7M | $4.0M | No debt tags | $286K | 20-F 2026-04-27 |
| FY 2024 2024-12-31 | $8.0M | -$8.3M | -$9.4M | $4.6M | No debt tags | $8.0M | 20-F 2025-04-10 |
| FY 2023 2023-12-31 | $6.5M | $23.9M | -$35.8M | $5.6M | No debt tags | $6.5M | 20-F 2025-04-10 |
| FY 2022 2022-12-31 | $61.8M | -$71.7M | -$29.2M | $20.0M | $115.2M | $61.8M | 20-F 2025-04-10 |
| FY 2021 2021-12-31 | $85.8M | -$97.7M | -$65.0M | $29.5M | $83.6M | $85.8M | 20-F 2024-04-08 |
| FY 2020 2020-12-31 | $64.4M | -$76.2M | -$48.6M | $29.3M | $81.4M | $64.4M | 20-F 2023-04-28 |
| FY 2019 2019-12-31 | $6.3M | -$42.3M | -$40.7M | $29.0M | No debt tags | $6.3M | 20-F 2022-03-17 |
| FY 2018 2018-12-31 | $8.4M | -$38.8M | -$34.5M | $29.0M | No debt tags | $8.4M | 20-F 2021-03-18 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-13 |
| Latest annual report | 20-F | 2026-04-27 |
| Latest quarterly / interim | 6-K | 2026-11-02 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.4% |
| 1 month | -27.2% |
| 3 months | -37.0% |
| Year to date | -63.6% |
| 1 year | -65.0% |
| From 52-week high | -73.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MDCX | Medicus Pharma Ltd. Common Stock | $1.69 | -13.33% | $3.2M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| XBIO | Xenetic Biosciences Inc. | $1.49 | -10.24% | $3.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier